This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Oncolytic Viruses / Non-viral Gene Therapy Delivery
November 30 - December 1, 2022
Digital Conference8:00AM EST // 1:00PM GMT // 2:00PM CET

Don Haut
CEO & Director at Carmine Therapeutics, USA

Profile

Dr. Haut is CEO of Carmine Therapeutics – a leader in non-viral gene therapy. In a career spanning academic science, consulting, business development, Dr. Haut has held executive leadership roles, and Board of Directors roles in biotech, pharmaceutical, and medical device companies, and has completed transactions exceeding $8 billion and been instrumental in multiple product launches. Originally trained as a molecular biologist before joining McKinsey, he has since held senior business roles at 3M Company, Smith & Nephew, The Medicines Company, Histogenics and AskBio. He earned his PhD in Molecular Biology from the Medical School at the University of Missouri-Columbia and an MBA from Washington University’s Olin School of Business.

Agenda Sessions

  • Gene Delivery using Red Blood Cell Extracellular Vesicles

    8:35am